{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-026166","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.698804+00:00","generated_at":"2026-05-31T09:43:07.838271+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Genprex granted Singapore patent for Reqorsa with anti-PD-1 antibodies through 2037","bullets":["Singapore Patent Office grants patent covering Reqorsa (quaratusugene ozeplasmid) in combo with anti-PD-1 antibodies until 2037.","Patent expands on previously granted patents in U.S., Japan, Mexico, Russia, Australia, Chile, China, and Korea.","Korean patent also claims Reqorsa with PD-L1 antibodies; Genprex plans similar filings in U.S., Brazil, Canada, China, Europe, Israel.","Patent supports Acclaim-3 Phase 1/2 trial for ES-SCLC maintenance therapy combining Reqorsa with Tecentriq."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-026166","json":"https://secwatch.observer/filing/0001437749-24-026166.json","markdown":"https://secwatch.observer/filing/0001437749-24-026166.md","text":"https://secwatch.observer/filing/0001437749-24-026166.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924026166/0001437749-24-026166-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774924026166/gnpx20240803_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:43:07.838271+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}